Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05342623 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
A Phase 3 study, sponsored by Cara Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 286
- Enrollment target
NCT05342623 is a Phase 3 study that was terminated before completion, run by Cara Therapeutics. The registered enrollment target is 286 participants.
The verdict
NCT05342623, a Phase 3 study, was terminated before completion, sponsored by Cara Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 286 participants
- Enrollment target
Study Summary
This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of oral difelikefalin administered as a 1 mg tablet once daily compared to placebo in reducing the intensity of itch in advanced chronic kidney disease (CKD) patients with moderate-to-severe pruritus. This study is comprised of an Efficacy Assessment Phase and a Long-term Extension Phase. The Efficacy Assessment Phase includes a double-blind 12-week Treatment Period (Treatment Period 1), and the Long-term Extension Phase includes a double-blind Treatment Period (Treatment Period 2) of up to 52 weeks.
Interventions
- DRUG Placebo Oral Tablet
- DRUG Difelikefalin 1 mg Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2022-05-17 |
| Est. Completion | 2024-02-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05342623
The ClinicalTrials.gov registry entry for NCT05342623 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 286 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cara Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT05342623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05342623 about?
NCT05342623 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus". This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of oral difelikefalin administered as a 1 mg tablet once daily compared to placebo in reducing the intensity of itch in advanced chronic kidney disease (CKD) patients with moderate-to-severe...
What is the current status of trial NCT05342623?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 286 participants. The study started on 2022-05-17. Estimated completion is 2024-02-29.
What interventions are being tested in trial NCT05342623?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Difelikefalin 1 mg Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT05342623?
This trial is sponsored by Cara Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.